erythromycin has been researched along with Bone Loss, Osteoclastic in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, BD; Li, XH; Ren, W; Wooley, PH | 1 |
Hanazawa, S; Kitano, S; Miyata, Y; Takeda, H | 1 |
Helovuo, H; Paunio, K | 1 |
1 trial(s) available for erythromycin and Bone Loss, Osteoclastic
Article | Year |
---|---|
Effects of penicillin and erythromycin on the clinical parameters of the periodontium.
Topics: Adult; Bone Resorption; Dental Plaque; Erythromycin; Female; Gingivitis; Humans; Male; Middle Aged; Penicillins; Periodontal Abscess; Periodontal Diseases; Periodontitis; Periodontium; Radiography; Single-Blind Method | 1989 |
2 other study(ies) available for erythromycin and Bone Loss, Osteoclastic
Article | Year |
---|---|
Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
Topics: Animals; Anti-Bacterial Agents; Bone Resorption; Carrier Proteins; Cell Line; Erythromycin; Gene Expression; Interleukin-1; Macrophages; Membrane Glycoproteins; Mice; NF-kappa B; Osteoclasts; Prosthesis Failure; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Skull; Tumor Necrosis Factor-alpha | 2004 |
Porphyromonas gingivalis lipopolysaccharide-stimulated bone resorption via CD14 is inhibited by broad-spectrum antibiotics.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Bone Resorption; Chloramphenicol; Erythromycin; Gene Expression; Interleukin-1; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Mice; Osteoclasts; Porphyromonas gingivalis; RNA, Messenger; Skull; Streptomycin; Tetracycline | 1997 |